| Field | Specification |
|---|---|
| Alternative names | LV-CMV-mCherry-Puro | LV-CMV-mCherry | LV-mCherry | CMV-mCherry-Puro Lentivirus |
| Applications | |
| Purity | |
| Titer | |
| Promoter | |
| Reporter/Tag | |
| Expression regulation | |
| Selection marker | Puromycin |
| Biosafety level | |
| Storage buffer | |
| Catalog no. (Mfr.) | |
| Main SKU |
Vector Overview
LV-CMV-mCherry-Puro is a pre-packaged recombinant lentiviral vector that drives expression of mCherry red fluorescent protein under the control of the cytomegalovirus (CMV) immediate-early promoter. The CMV promoter is one of the most widely used strong constitutive promoters in mammalian expression systems. Derived from the human cytomegalovirus immediate-early regulatory region, it drives high-level expression in a broad range of cell types, though expression may undergo silencing in certain primary or stem cell contexts over prolonged culture. mCherry is a bright, monomeric red fluorescent protein with fast maturation kinetics and good photostability. It is spectrally distinct from GFP, enabling dual-color imaging when both reporters are used in the same experiment. The puromycin resistance cassette allows efficient antibiotic selection of successfully transduced cells, enabling rapid generation of stable, enriched cell populations. Lentiviral delivery ensures efficient, stable integration into the host genome of both dividing and non-dividing mammalian cells. LV-CMV-mCherry-Puro is supplied in a ready-to-use format, eliminating the need for vector construction, packaging, and titration.
Technical Details
| Catalog No. | SL100276 |
|---|---|
| Promoter | CMV |
| Reporter / Tag | mCherry |
| Expression Regulation | Constitutive |
| Selection Marker | Puromycin |
| Titer | >1E+9 TU/mL |
| Storage Buffer | PBS |
| Purity / Grade | In vivo grade and OK for both in vitro tissue culture infection and in vivo injection * Concentrated via PEG precipitation followed by ultra-centrifugation at 25000 rpm |
| Biosafety Level | BSL-2 |
| Sizes | 25 uL; 25 uL x 2 |
Applications
- Lentiviral Transduction: stable delivery of the cassette into dividing and non-dividing cells for long-term expression.
Biosafety
LV-CMV-mCherry-Puro is a pre-packaged lentiviral vector classified as BSL-2. Handle in a certified biosafety cabinet under institutional BSL-2 practices, decontaminate all contact surfaces and waste, and follow local regulations for viral vector work.
Safety & Handling
Store at -80°C; avoid repeated freeze-thaw cycles. Ships on dry ice. Supplied in PBS. For research use only; not for diagnostic or therapeutic use.
Can't find the lentiviral construct you need, or want to adjust key design elements? Contact us to discuss custom LV design and optional add-ons.
Common customization requests
- Insert / payload: replace the gene/sequence, swap to a different isoform, add mutations, or optimize cloning features.
- Expression design: change promoter (e.g., CMV/EF1α/PGK), add enhancers, or adjust regulatory elements.
- Reporters: add/swap GFP/RFP/mCherry/luciferase (single or dual reporters where applicable).
- Selection markers: add/swap puromycin/blasticidin/neomycin or fluorescent selection options.
- Vector format: switch between OE, shRNA, CRISPR (sgRNA/Cas systems), or control vectors (where supported).
Add-ons you can request
- Control viruses: empty vector, non-targeting shRNA, reporter-only controls, or matched backbone controls.
- Packaging / format: concentration options, aliquoting, or custom fill volume for screening workflows.
- Documentation: construct map/sequence confirmation package (as available) and batch documentation.
What to include in your request
- Target cell type/model (cell line or primary cells) and intended readout (reporter, knockdown, OE, etc.)
- Insert sequence (FASTA) or reference ID, plus any required tags/mutations
- Promoter, reporter, and selection marker preferences
- Desired scale and preferred format (aliquots / concentration requests)
Email us at support@biohippo.com or use the Talk to a Scientist request form.
Vargas-Valderrama A, Ponsen A, Gall M, Clay D, Jacques S, Manoliu T, et al. (2022) Endothelial and hematopoietic hPSCs differentiation via a hematoendothelial progenitor. Stem Cell Res Ther, 13(1), 254-254. 10.1186/s13287-022-02925-w
Craig RA, Fox BM, Hu C, Lexa KW, Osipov M, Thottumkara AP, et al. (2022) Discovery of Potent and Selective Dual Leucine Zipper Kinase/Leucine Zipper-Bearing Kinase Inhibitors with Neuroprotective Properties in In Vitro and In Vivo Models of Amyotrophic Lateral Sclerosis. J Med Chem, 65(24), 16290-16312. 10.1021/acs.jmedchem.2c01056
Li B (2021) UNDERSTANDING CARDIOMYOCYTE DIFFERENTIATION FROM PLURIPOTENT STEM CELLS. Thesis.